{"id":"W2168482167","doi":"10.1158/1078-0432.ccr-03-0244","title":"Treatment of HER-2/<b> <i>neu</i> </b> Overexpressing Breast Cancer Xenograft Models with Trastuzumab (Herceptin) and Gefitinib (ZD1839): Drug Combination Effects on Tumor Growth, HER-2/<b> <i>neu</i> </b> and Epidermal Growth Factor Receptor Expression, and Viable Hypoxic Cell Fraction","year":2004,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":81,"is_retracted":false,"has_abstract":true,"ca_institutions":"Stemcell Technologies; University of British Columbia; BC Cancer Agency","funders":"BC Cancer Agency","keywords":"Gefitinib; Trastuzumab; Medicine; Cancer research; Epidermal growth factor receptor; In vivo; Estrogen receptor; Breast cancer; Growth inhibition; Cell growth; Cancer; Internal medicine; Pharmacology; Biology","routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.001382115,0.0006359651,0.00137335,0.0004230391,0.0005490114,0.0001903556,0.0002478084,0.0003729238,0.0001991105],"category_scores_gemma":[0.0002805428,0.0004864484,0.0001693348,0.0007151874,0.001310902,0.0006338054,0.0002127932,0.00152051,0.00001123532],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001256876,"about_ca_system_score_gemma":0.001274361,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.006145678,"about_ca_topic_score_gemma":0.0002063828,"domain_scores_codex":[0.9930032,0.001084014,0.001079524,0.00161183,0.00194849,0.001272932],"domain_scores_gemma":[0.994379,0.002430163,0.0003764241,0.0006345224,0.001049795,0.001130131],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","study_design_scores_codex":[0.03783716,0.01229504,0.423911,0.01209349,0.0006934237,0.0005814672,0.006056848,0.000462296,0.3295547,0.0004166172,0.00700895,0.169089],"study_design_scores_gemma":[0.07755496,0.02856139,0.2085799,0.01349097,0.0005381617,0.0003765378,0.0021006,0.001981869,0.6583262,0.00342144,0.0028492,0.002218778],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.987444,0.00412655,0.0001202559,0.004446451,0.0002016362,0.002705093,0.0002935237,0.00009655385,0.0005659827],"genre_scores_gemma":[0.9826313,0.01396547,0.0009012797,0.000409578,0.0006092992,0.0009350271,0.00003116505,0.0001708041,0.0003461091],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.3287715,"threshold_uncertainty_score":0.9997587,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.08032479363375436,"score_gpt":0.4131441111757406,"score_spread":0.3328193175419862,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}